Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · IEX Real-Time Price · USD
0.590
+0.029 (5.17%)
At close: Jul 19, 2024, 4:00 PM
0.600
+0.010 (1.69%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Company Description
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States.
The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata.
Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Forte Biosciences, Inc.
Country | United States |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 9 |
CEO | Dr. Paul A. Wagner Ph.D. |
Contact Details
Address: 3060 Pegasus Park Drive, Building 6 Dallas, Texas 75247 United States | |
Phone | (310) 618-6994 |
Website | fortebiorx.com |
Stock Details
Ticker Symbol | FBRX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001419041 |
CUSIP Number | 34962G109 |
ISIN Number | US34962G1094 |
Employer ID | 26-1243872 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Paul A. Wagner Ph.D. | Chief Executive Officer, President and Chairman |
Antony A. Riley CPA | Chief Financial Officer |
Christopher Roenfeldt | Chief Operating Officer |
Steven Ruhl | Chief Technical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 19, 2024 | PRE 14A | Other preliminary proxy statements |
Jun 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Jun 14, 2024 | 8-K | Current Report |
May 13, 2024 | 10-Q | Quarterly Report |
May 13, 2024 | 8-K | Current Report |
Apr 29, 2024 | 10-K/A | [Amend] Annual report |
Apr 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 18, 2024 | 10-K | Annual Report |
Mar 18, 2024 | 8-K | Current Report |
Feb 16, 2024 | 8-K/A | [Amend] Current report |